BC Innovations | Aug 29, 2019
Emerging Company Profile

Hesperos: uniting organs on a chip

Hesperos hopes to supplant animal models as the standard preclinical testing ground by designing reconfigurable, multi-organ chips to predict drug efficacy and toxicity early in development. The organ-on-a-chip company spun out of the Tissue Chip...
BC Extra | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now...
BC Week In Review | Oct 26, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
BC Extra | Oct 24, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Extra | Aug 8, 2017
Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
BC Innovations | Jul 27, 2017
Product R&D

Spheres of influence

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...
BC Innovations | May 16, 2017
Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Arthritis; pain Cell culture and mouse studies suggest a pyrazolopyridine-based GPR4 inhibitor could help treat arthritis or pain. Chemical synthesis of pyrazolopyridine analogs and testing in a human cell line yielded an oxadiazole-containing compound...
BC Week In Review | Jan 13, 2017
Company News

Futura, Stada Arzneimittel deal

Futura granted Stada’s Thornton & Ross Ltd. subsidiary rights to commercialize pain candidate TPR100 in the U.K. Thornton & Ross will submit a regulatory application next half. Futura will receive an undisclosed upfront payment and...
BC Week In Review | Oct 31, 2016
Financial News

Futura Medical completes placing

Futura Medical plc (LSE:FUM), Guildford, U.K.  Business: Drug delivery, Neurology, Genitourinary  Date completed: 2016-10-27  Type: Placing  Raised: L12 million ($14.7 million)  Shares: 21.1 million  Price: 57p  Shares after offering: 120.1 million  Placement agent: N+1 Singer ...
Items per page:
1 - 10 of 431